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Abstract  
The aetiology and pathogenesis of Myelodysplastic Syndrome (MDS) remain poorly characterized. One 
mechanism invoked to explain the apparent discrepancy between cellular marrow and peripheral blood 
cytopenias in patients with MDS is programmed cell death (apoptosis), which occurs with increased 
frequency in MDS marrow. Higher rates of apoptosis have been observed in Refractory Anaemia (RA) and 
Refractory Anaemia with Excess Blasts (RAEB) compared with transforming MDS or acute leukaemia while 
others have found increased rates in late stages of disease. Cell death may be triggered by activated T cells 
(in an attempt to eliminate the armful clone), secretion of death proteins/inhibitory cytokines (TNF , 
Fas/Fas-L) and interleukin-6, expression of the pro-apoptotic proteins of Bcl-2 family, and/or through a 
relative deficiency in hematopoietic growth factors (stromal defects). Increased expression and release of 
TNF-related apoptosis inducing ligand (TRAIL), also known as Apo2 ligand (Apo2L) at the bone marrow 
level is likely to impair erythropoiesis and to contribute to the degree of anaemia, the major clinical feature 
of MDS. The exact mechanism by which TRAIL eliminates tumour cells preferentially or selectively is not 
known. One possibility is differential expression of agonistic receptors 1 and 2 (TRAIL-R1 and -R2), also 
known as death receptors, DR4 and DR5, and antagonistic or modulatory receptors, TRAIL-R3 and R4, also 
known as decoy receptors, DcR1 and DcR2. An alternative mechanism would be differential expression of, 
or functional defects in, cytoplasmatic inhibitors of apoptosis such as FADD-like converting enzyme (ICE)–
inhibitory protein (FLIP) or other inhibitory IL -1 apoptotic proteins (IAP) likely survivin. Although 
increased programmed cell death in MDS may occur as an early rescue or compensatory response to 
deregulated clonal proliferation, it may also represent a pathophysiologic consequence of the epigenetic 
changes associated with the disease biology of MDS as we have already referred (EHA 2008). However the 
MDS remain an inadequately characterized disorder and novel strategies for studying disease pathogenesis 
and progression continue to shape our understanding and approach to diagnosing and treating. With this 
study we hope to contribute to the identification of molecular markers involved in apoptotic signalling 
pathways that could be related with MDS and that could interfere with the prognosis, namely the evolution to 
acute leukaemia, and with the therapeutic approach. For this purpose we have examined the expression of 
proteins involved in apoptotic pathways (membranar and mitochondrial) namely Bax, Bcl-2, p53, Fas/FasL, 
TRAIL/TRAIL-Rs and survivin, in CD34 bone marrow cells populations collected at diagnosis from 23 
patients with de novo MDS and in 6 ITP (non-malignant controls). The expression of the proteins was 
evaluated by flow cytometry using monoclonal antibodies. The median age was 77 years (33–84), 
M/F=12/11, WHO subtypes: RCMD (n=12), RA (n=2), RCMD-RS (n=1), CMML (n=2), RAEB-2 (n=5), 5q- 
syndrome (n=1) and IPSS: low (n=6), intermediate-1 (n=6) and intermediate-2 (n=2), in patients with 
cytogenetic results. Two of the patients (both RAEB-2) evolve to acute leukemia, with a median follow-up of 
24 months (12–65). Our results show that CD34 MDS patients cells have an higher Bax/Bcl-2 ratio, Bax, 
survivin, cit c, TRAIL-R3 and TRAIL-R4 levels and lower levels of Bcl-2, TRAIL, TRAIL-R1, Fas and Fas-
L compared with non-malignant controls. However RA patients have the higher Bax, Fas, Fas-L, TRAIL-R3 
and survivin levels while RAEB-2 patients have the lowest. This subtype of patients (RAEB-2) also show a 
decrease in Bax/Bcl-2 ratio, lower levels of TRAIL-R2 and higher levels of Bcl-2. This study suggest that 
apoptosis deregulation may be implicated in MDS. However, in RA an increase in apoptosis predominates 
while in RAEB the resistance to apoptosis may contribute to a less favourable prognosis and may influence 
the transition to acute myeloid leukaemia. Furthermore, we hope that the identification of all that molecular 
markers may contribute to identify new risk patients groups and molecular therapeutic targets.  
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